UPDATE : Monday, December 17, 2018
상단여백
Celltrion Healthcare’s sell-off of domestic sales right raises window-dressing controversy by Nam Doo-hyun 2018-12-17 12:48
Samsung BioLogics’ market cap rises after accounting issue by Nam Doo-hyun 2018-12-13 15:33
‘Bispecific antibody market offers promising outlook’ by Nam Doo-hyun 2018-12-12 16:27
Samsung BioLogics, Celltrion shares soar despite uncertainty by Lee Han-soo 2018-12-12 16:27
Machine learning finds biomarker for rare Castleman Disease by Lee Hye-seon 2018-12-11 17:11
라인
Viromed finds prostate hyperplasia treatment effect in natural substance by Lee Han-soo 2018-12-11 14:55
Samsung BioLogics resumes trading despite controversies by Lee Han-soo 2018-12-11 10:50
Celltrion unveils clinical trial results for rituximab biosimilar in US by Lee Han-soo 2018-12-06 11:11
Samsung BioLogics, Saint-Gobain sign supply agreement by Lee Han-soo 2018-12-05 14:01
Chong Kun Dang launches world’s 1st 2nd-generation anemia biosimilar by Lee Han-soo 2018-12-04 11:18
라인
‘Rules to be tougher on patent transfer due to ToolGen case’ by Nam Doo-hyun 2018-11-29 11:48
Celltrion wins FDA nod for rituximab biosimilar by Lee Han-soo 2018-11-29 10:50
Samsung BioLogics files administrative suit to refute accounting fraud ruling by Nam Doo-hyun 2018-11-28 15:30
Pharmaceuticals, biotechs rise with KOSPI rebound by Nam Doo-hyun 2018-11-27 11:53
Celltrion’s Remsima tops global sale of ₩1 trillion by Lee Han-soo 2018-11-23 14:54
라인
Operating income declines at top 10 biotechs on KOSDAQ by Nam Doo-hyun 2018-11-22 11:15
Celltrion CEO involved in alleged ‘gapjil’ scandal by Lee Han-soo 2018-11-21 16:02
US data crucial for Korean biosimilars after success in Europe by Nam Doo-hyun 2018-11-21 15:29
FDA OKs sale of Celltrion's HIV biosimilar by Lee Han-soo 2018-11-21 12:57
Intron Bio inks ₩750 billion licensing deal for anti-superbug drug by So Jae-hyeon 2018-11-20 15:00
여백
여백
여백
Back to Top